Chang Gung Memorial Hospital
Kwei-shan, Toayuan County, Taiwan
NCT Number: NCT01655160
The purpose of this study will evaluate the long-term benefits, optimal dose and mechanisms of mirror therapy and its effects on physiological markers.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Kwei-shan, Toayuan County, Taiwan
This trial is to examine whether (1) the immediate effects of treatment intensity in MT would occur on sensorimotor impairments and functional performance in patients with subacute stroke; (2) the long-term benefits of treatment intensity in MT on functionality can persist for six months after treatment finished; and (3) the MT could result in cortical/movement reorganization as well as the changes in physiological markers.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
Other names: MT-LI
The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
Other names: MT-MI
The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
Other names: MT-HI
The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
Other names: CI
Time frame: Baseline, change from baseline in FMA at 2 weeks, and change from baseline in FMA at 4 weeks
The UE subscale of the FMA (max. score 66) uses a 3-point ordinal scale to assess motor impairment.
Time frame: Baseline, change of ARAT at 2 weeks, and change of ARAT at 4 weeks
ARAT will be used to assess the motor function of UE. A total of 19 items are to test the movement of grasp, grip, pinch, and gross motor, with a scale of 0-3 for each item (maximal of 57).
Time frame: Baseline, change of MAL at 2 weeks, and change of MAL at 4 weeks
The MAL is a semi-structured interview of patients to assess the amount of use (AOU) and quality of movement (QOM) of the affected upper extremity in 30 important daily activities using a 6-point ordinal scale. Higher scores indicate better performance.
Time frame: Baseline, change of ABILHAND Questionnaire at 2 weeks, and change of ABILHAND Questionnaire at 4 weeks
ABILHAND questionnaire is an inventory of 56 manual activities that uses a 3-point ordinal scale to measure subjectively perceived difficulty in performing everyday bimanual activity.
Time frame: Baseline, change of AAP at 2 weeks, and change of AAP at 4 weeks
AAP will be applied to indicate the level of participation in household and community activities. This profile includes 21 activities in the four areas: domestic chores, household maintenance, service to others, and social activities.
Time frame: Baseline and change of fMRI at 4 weeks
uses the blood oxygenation level-dependent (BOLD) response to evaluate the brain reorganization after intervention.
Time frame: Baseline and change from baseline in physiological marker measures at 4 weeks
measure inflammatory markers, oxidative stress markers, and erythrocyte deformability.
Chang Gung Memorial Hospital
Other
Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke: Outcomes in Brain and Movement Reorganization, Sensorimotor and Daily Functions, and Measures of Physiological Markers.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03453008
Brain Diseases, Cardiovascular Diseases
Toulouse, France
View Trial DetailsNCT06509542
Brain Diseases, Cardiovascular Diseases
Lamalou-les-Bains, France
View Trial DetailsNCT05241457
Brain Diseases, Cardiovascular Diseases
Schenectady, New York, United States
View Trial DetailsNCT04028999
Brain Diseases, Cardiovascular Diseases
Toulouse, France
View Trial Details